Can GLP-1 drugs improve breast cancer survival?
Yes. In this large study of 841,831 women with early-stage breast cancer, those who took GLP-1 drugs like Ozempic had a 65% lower risk of dying over 10 years if they had obesity, and a 56% lower risk of the cancer coming back. The benefits were even larger in women with type 2 diabetes.
GLP-1 drugs are a newer class of medication. They include semaglutide (Ozempic, Wegovy) and similar drugs. Doctors first used them to treat type 2 diabetes. Now they are also used for weight loss. This study looked at whether these drugs might also help women who have been diagnosed with breast cancer.
The research team pulled records from the TriNetX US Collaborative Network, a database that links de-identified patient charts from many hospitals. They identified 841,831 women diagnosed with stage I, II, or III breast cancer between 2006 and 2023. Then they compared women who had used GLP-1 drugs to women who had not, tracking who lived, who died, and whose cancer returned.
What the data show
The differences were striking. Among women with obesity, those who took GLP-1 drugs had a hazard ratio of 0.35 for death from any cause, meaning a 65% lower risk over 10 years compared with similar women not on these drugs. Their risk of the cancer coming back fell by 56%, with a hazard ratio of 0.44.
The numbers were even more dramatic in women with type 2 diabetes. Compared with diabetic women treated with insulin or metformin, those on GLP-1 drugs had a hazard ratio of 0.09 for death, and a hazard ratio of 0.33 for recurrence-free survival. To put that in plain English, the GLP-1 group fared dramatically better on both measures than women taking older diabetes drugs.
Dr. Kumar’s Take
I want to be honest with you about how I read this paper. The size of the benefit here, especially in the diabetic group, is so large that my first reaction is skepticism. A 91% lower risk of death is the kind of number that almost never holds up once you run a real randomized trial. It usually shrinks. Sometimes it disappears.
That said, the biology is plausible. Obesity and high insulin levels are known drivers of breast cancer growth, and GLP-1 drugs lower weight, blood sugar, and insulin all at once. So a real effect would not surprise me. I just suspect the true effect is smaller than what this study shows. We need randomized trials before anyone should start a GLP-1 drug specifically to fight cancer.
How strong is the evidence?
This was a retrospective cohort study, which means the researchers looked back at records that already existed. They did not assign women to take GLP-1 drugs or not. That matters. Women who get prescribed these medications tend to be different from women who do not, in ways that can affect survival. They may be more engaged with their doctors, have better insurance, or be healthier overall in ways the database cannot capture.
Statisticians try to adjust for these differences, but they can never fully erase them. The authors themselves point this out. They write clearly that an observational study cannot prove cause and effect, and that randomized trials are needed to know whether GLP-1 drugs truly improve cancer outcomes.
Who might benefit most
If the effect is real, the women most likely to benefit are those who already have a reason to take a GLP-1 drug. That means women with type 2 diabetes, women with obesity, or women whose doctors are considering one of these medications for weight management. For those patients, the possibility of a cancer benefit is an interesting bonus to weigh alongside the known effects on blood sugar and weight.
For women without diabetes or obesity, this study does not yet justify starting a GLP-1 drug to lower cancer risk. The drugs have side effects, including nausea, pancreatitis, and possible thyroid risks. The risk-benefit math only makes sense when there is already a clear reason to take the medication.
Practical Takeaways
- If you have been diagnosed with breast cancer and you also have type 2 diabetes or obesity, ask your oncologist and endocrinologist whether a GLP-1 drug might fit into your treatment plan for those conditions.
- Do not stop or change any cancer treatment based on this study, since GLP-1 drugs are not a substitute for standard breast cancer care like surgery, radiation, hormone therapy, or chemotherapy.
- Keep in mind that the 65% and 91% reductions reported here come from an observational study, so the true effect is likely smaller and will need randomized trials to confirm.
- If you are already taking a GLP-1 drug for weight or diabetes, this is one more reason to stay engaged with your primary care doctor and cancer screening schedule.
Related Studies and Research
- Women’s Health Initiative: what 20 years of follow-up really shows about HRT and breast cancer
- Omega-3 fatty acids and type 2 diabetes risk: what the latest research reveals
- Coffee reduces mortality risk: prospective cohort evidence
- Enough: why the WHI continues to misrepresent its own breast cancer data
FAQs
Should women with breast cancer ask their doctor about starting a GLP-1 drug?
Not based on this study alone. GLP-1 drugs like Ozempic and Wegovy are approved for type 2 diabetes and obesity, not for cancer treatment. If you have one of those conditions and also have breast cancer, it is a reasonable conversation to have with your oncologist and endocrinologist together. If you do not have diabetes or significant obesity, there is no current evidence that justifies the side effects and cost of these drugs for cancer prevention. Randomized trials are needed first.
Why might GLP-1 drugs help with breast cancer in the first place?
The leading idea is that obesity and high insulin levels feed breast cancer growth, especially the hormone-positive types. GLP-1 drugs lower body weight, reduce insulin levels, and improve blood sugar control, all of which could in theory slow tumor growth or recurrence. There may also be direct effects on inflammation and the immune system, though these are still being studied. None of this is proven in humans yet, but the biology is consistent with the observed pattern.
How confident should I be in a 91% lower risk of death?
You should be cautious. Effect sizes that large in observational studies almost always shrink when researchers run a randomized trial. The most likely reason is that women prescribed GLP-1 drugs differ from women who are not, in many small ways that add up. Those differences, called confounders, can make a treatment look much better than it really is. The 91% figure should be read as a signal worth investigating, not as a confirmed effect.
Bottom Line
In a database study of more than 800,000 women with early-stage breast cancer, those who took GLP-1 drugs had dramatically lower rates of death and cancer recurrence over 10 years. The signal is large enough to take seriously, especially given the plausible biology linking obesity, insulin, and breast cancer. But observational studies cannot prove cause and effect, and the size of the benefit will likely shrink in randomized trials. For now, GLP-1 drugs remain a treatment for diabetes and obesity, with a promising and unproven side benefit that deserves rigorous testing.
